The recombinant novel coronavirus vaccine, jointly developed by Zhifei Longkema Co., Ltd. (a wholly-owned subsidiary of Chongqing Zhifei Biological Products Co., Ltd.) and Institute of Microbiology of the Chinese Academy of Sciences, started the second phase clinical trial in Hunan’s Xiangtan County Center for Disease Control and Prevention to evaluate the safety and immunogenicity of the vaccine.
The vaccine adopts recombinant DNA technology, takes the unique dimer of the receptor-binding domain (RBD) of novel coronavirus spike glycoprotein (S protein) as an antigen, and is supplemented with traditional adjuvant. It does not carry any form of exogenous tag and has unique conformation, high immunogenicity, and excellent safety.
After obtaining National Medical Products Administration’s drug clinical trial approval, on June 23, the first phase clinical trials were carried out in the Second Affiliated Hospital of Chongqing Medical University and Beijing Chaoyang Hospital of Capital Medical University respectively to evaluate the safety and tolerance of vaccines, and now the second phase clinical trials are started. Zhifei Longkema Co., Ltd. has been committed to the development and production of new vaccines for human use.
After the outbreak of COVID-19, Chongqing Zhifei Biological Products Co., Ltd. quickly started the research COVID-19 vaccine and launched the first recombinant subunit COVID-19 vaccine approved for clinical trials in China. So far, the construction for the production workshop of the COVID-19 vaccine and the quality assurance system is accelerating.
For any inquiries, please email firstname.lastname@example.org